Richard Jacques

TL;DR: There is considerable variation in the consent, recruitment and retention rates in publicly funded RCTs and investigators should bear this in mind at the planning stage of their study and not be overly optimistic about their recruitment projections.

TL;DR: It is shown how significance levels other than the traditional 5% should be considered to provide preliminary evidence for efficacy and how estimation and confidence intervals should be the focus to provide an estimated range of possible treatment effects.

TL;DR: Bone turnover markers were used to identify women who responded to bisphosphonate treatment for osteoporosis and suggest that biochemical assessment of response is a useful tool for the management of women with postmenopausal osteoporeosis.

TL;DR: Estimates of the percentage of treatment effect explained may be higher than in previous studies because of high compliance with zoledronic acid (due to its once‐yearly intravenous administration), which may have underestimated the relationship between BMD change and the effect of treatment on fracture risk.

TL;DR: Lower 25(OH)D may not reflect at-risk skeletal health in obese people, and BMI should be considered when interpreting serum 25( OH)D as a marker of vitamin D status.